P14ARF 在肿瘤进展过程中被下调，并预测了人类乳腺癌的临床结局。

P14ARF is down-regulated during tumour progression and predicts the clinical outcome in human breast cancer.

机构信息

London Breast Institute, the Princess Grace Hospital, 45 Nottingham Place, London W1U 5NY, UK.

出版信息

Anticancer Res. 2013 May;33(5):2185-9.

Abstract

UNLABELLED

The objective of this study was to determine the mRNA expression for p14 and p16 in a cohort of women with breast cancer.

MATERIALS AND METHODS

Breast cancer specimens (N= 127) and normal tissue (N=23) specimens were studied. Transcript levels were determined using quantitative polymerase chain reaction (PCR), and were correlated with clinicopathological data collected over 10 years.

RESULTS

Higher p14 mRNA transcript levels were associated with non-cancerous background tissue specimens (median copy numbers: 103 vs. 4, p=0.0095), with better overall and disease-free survival, and in TNM2 stage tumours (TNM2 vs. TNM1, 27.2 vs. 3.5, p=0.049; TNM1/TNM2 vs. TNM3/4, 26 vs. 2, p=0.009). There was no significant relationship between p16 levels and clinicopathological parameters. A correlation between p14 and human telomerase reverse transcriptase (hTERT) levels was observed (r=0.406, p=0.00005).

CONCLUSION

p14 expression seems to increase initially in early breast cancer and decrease with further tumour progression. p14 may be induced to counteract immortalisation and hTERT surge.

摘要

目的

本研究旨在确定 p14 和 p16 在乳腺癌患者队列中的 mRNA 表达。

材料与方法

研究了 127 例乳腺癌标本和 23 例正常组织标本。采用实时定量聚合酶链反应（PCR）测定转录水平，并与 10 年来收集的临床病理数据相关联。

结果

p14 mRNA 转录水平较高与非癌性背景组织标本相关（中位数拷贝数：103 与 4，p=0.0095），与整体和无病生存相关，且与 TNM2 期肿瘤相关（TNM2 与 TNM1，27.2 与 3.5，p=0.049；TNM1/TNM2 与 TNM3/4，26 与 2，p=0.009）。p16 水平与临床病理参数之间无显著相关性。观察到 p14 与人类端粒酶逆转录酶（hTERT）水平之间存在相关性（r=0.406，p=0.00005）。